Abstract | OBJECTIVE: METHOD: Twenty-one DS patients with severe cognitive impairment were assigned to take donepezil (3 mg daily) or a placebo for 24 weeks, and evaluated for activities in daily lives by concisely modified International Classification of Functioning, Disability and Health (ICF) scaling system. RESULTS: ICF scores significantly increased without any adverse effects in the donepezil group in comparison to those in the placebo control. Among the individual functions tested, there was a dramatic improvement in the global mental functions and in specific mental functions. CONCLUSIONS:
|
Authors | Tatsuro Kondoh, Atsushi Kanno, Hiroshi Itoh, Mikiro Nakashima, Ryoko Honda, Michio Kojima, Mitsuru Noguchi, Hideyuki Nakane, Hidetsugu Nozaki, Hitoshi Sasaki, Toshiro Nagai, Rika Kosaki, Naoko Kakee, Torayuki Okuyama, Masafumi Fukuda, Masayuki Ikeda, Yoshisada Shibata, Hiroyuki Moriuchi |
Journal | International journal of psychiatry in medicine
(Int J Psychiatry Med)
Vol. 41
Issue 1
Pg. 71-89
( 2011)
ISSN: 0091-2174 [Print] United States |
PMID | 21495523
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Indans
- Nootropic Agents
- Piperidines
- Donepezil
|
Topics |
- Activities of Daily Living
- Adult
- Cognition Disorders
(complications, drug therapy)
- Donepezil
- Double-Blind Method
- Down Syndrome
(complications, drug therapy)
- Female
- Humans
- Indans
(therapeutic use)
- Middle Aged
- Neuropsychological Tests
- Nootropic Agents
(therapeutic use)
- Piperidines
(therapeutic use)
- Quality of Life
- Treatment Outcome
|